



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: **Linaprazan**
产品别名: 利那拉生; **AZD0865**

生物活性:				
Description	Linaprazan (AZD0865) inhibits gastric H ⁺ ,K ⁺ -ATPase by K ⁺ -competitive binding. (IC ₅₀ : 1.0 ± 0.2 μM) It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. In vitro: Linaprazan can inhibit the final step in acid secretion. Linaprazanreduced porcine renal Na ⁺ ,K ⁺ -ATPase activity by 9 ± 2%, demonstrating a high selectivity for H ⁺ ,K ⁺ -ATPase. In vivo: The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of Linaprazan would translate to a healing rate of 89% at 4 weeks.			
Solvent&Solubility	In Vitro: DMSO : ≥ 35 mg/mL (95.51 mM) * "≥" means soluble, but saturation unknown.			
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg
		1 mM	2.7288 mL	13.6441 mL
		5 mM	0.5458 mL	2.7288 mL
		10 mM	0.2729 mL	1.3644 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时, 请在 6 个月内使用, -20℃ 储存时, 请在 1 个月内使用。			
References	[1]. Gedda K et al. Mechanism of action of AZD0865, a K ⁺ -competitive inhibitor of gastric H ⁺ ,K ⁺ -ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205. [2]. Kahrilas PJ et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1385-91.			